Latest news with #NIPT
Yahoo
3 days ago
- Business
- Yahoo
Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) Market Set to Triple by 2033: Developments, Strategies, and Financial Insights of Leading Players Eurofins Scientific, Roche, Invitae Corp., Illumina and More
Challenges remain, such as limited awareness and high costs, but initiatives under Vision 2030 aim to improve access and affordability Saudi Arabian Non-Invasive Prenatal Testing Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Non-Invasive Prenatal Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to offering. The Saudi Arabia Non-Invasive Prenatal Testing Market is expected to reach US$ 143.09 million by 2033 from US$ 46.33 million in 2024, with a CAGR of 13.35% from 2025 to 2033. Advances in technology, greater knowledge, better insurance coverage, safety, and the growing incidence of genetic abnormalities are the main factors propelling the non-invasive prenatal testing industry in Saudi Arabia. Recent developments in genetic testing technology and growing awareness among medical professionals and pregnant parents have propelled the non-invasive prenatal testing (NIPT) sector in Saudi Arabia. By screening for chromosomal disorders including Down syndrome, trisomy 18, and trisomy 13 by examining fetal DNA in a mother's blood sample, NIPT provides a safer option to conventional prenatal diagnostics like amniocentesis. For many pregnant women, NIPT is an attractive option due to its non-invasive nature and zero chance of miscarriage. As a result, NIPT is increasingly being used as the recommended screening method in prenatal treatment. The availability of cutting-edge diagnostic technologies and the growing emphasis on healthcare modernization are two major factors propelling NIPT's expansion in Saudi Arabia. Saudi Arabia has been making significant investments in its healthcare system as part of Vision 2030, which involves expanding access to cutting-edge medical technology. As a result of this emphasis on healthcare development, NIPT is now more widely available, with more clinics and hospitals implementing the technology to provide patients with a safe, accurate, and dependable prenatal screening choice. Additionally, pregnant moms now have better access to these essential therapies because of the government's initiatives to provide healthcare services throughout the whole nation. Another important element driving the use of NIPT in Saudi Arabia is growing knowledge of genetic abnormalities and the advantages of early prenatal screening, in addition to advances in healthcare and technology. The need for trustworthy prenatal diagnostics has increased due to the rising prevalence of congenital disorders and chromosomal abnormalities. The public and medical professionals are therefore increasingly cognizant of the significance of genetic testing. It is anticipated that this knowledge, together with enhanced insurance coverage and the expanding availability of NIPT, would continue to propel market expansion in Saudi Arabia. Saudi Arabia's NIPT sector is expected to grow further as NIPT technologies continue to progress and are included into routine prenatal treatment. Growth Drivers for the Saudi Arabia Non-Invasive Prenatal Testing MarketTechnological Advancements The precision and dependability of genetic screening have been greatly enhanced by technological developments in non-invasive prenatal testing (NIPT). More accurate fetal DNA analysis is made possible by advancements in next-generation sequencing (NGS) and bioinformatics, which make it possible to identify a wider variety of genetic disorders. These developments have given expecting parents and medical professionals a more thorough screening tool by extending NIPT's capabilities beyond common chromosomal diseases like Down syndrome, trisomy 18, and trisomy 13 to encompass microdeletions and single-gene disorders. Because it enables the earlier, safer, and more accurate diagnosis of any genetic disorders without the hazards associated with intrusive testing procedures, NIPT has become the preferred option in prenatal care due to the integration of sophisticated technology. Rising Maternal Age One major factor contributing to the rising need for non-invasive prenatal testing (NIPT) is the aging of mothers. The chance of genetic abnormalities like Down syndrome rises as more women, especially those over 35, put off having children. Because older women are more likely to seek out sophisticated prenatal screening alternatives like NIPT, this demographic change has resulted in a greater prevalence of pregnancies among these women. A safer, non-invasive substitute for conventional invasive testing, NIPT offers precise early genetic problem diagnosis without the dangers of amniocentesis or CVS. Pregnant women are choosing NIPT more frequently as a result of growing knowledge of these advantages, which is driving up demand for these secure and trustworthy prenatal screening techniques. High Prevalence of Genetic Disorders Genetic problems, such as Down syndrome and other chromosomal abnormalities, are very common in Saudi Arabia. The increasing need for trustworthy prenatal screening techniques, such non-invasive prenatal testing (NIPT), has been greatly influenced by this. Without the danger of miscarriage that comes with intrusive tests like amniocentesis, NIPT provides a safer, more reliable method of identifying genetic abnormalities early in pregnancy. As more medical professionals and expecting parents become aware of the advantages of NIPT, it has emerged as a favored screening method, particularly for those who are more vulnerable because of advanced maternal age or a family history of genetic abnormalities. Therefore, the necessity for sophisticated, non-invasive testing like NIPT to promote improved prenatal care has increased due to the growing frequency of chromosomal disorders. Challenges in the Saudi Arabia Non-Invasive Prenatal Testing MarketLimited Awareness and Knowledge In Saudi Arabia, a major obstacle is the lack of knowledge and comprehension regarding non-invasive prenatal testing (NIPT). The goal, advantages, and limits of NIPT are not well known to many expectant mothers. According to a poll done between December 2023 and February 2024, 93.3% of respondents gave inaccurate answers to knowledge-related questions, while 64.6% of respondents were not aware of NIPT. Many women may not think of NIPT as a good choice for prenatal screening because of this ignorance, which can lead to poor decision-making. Lack of awareness may prevent pregnant moms from completely appreciating the advantages of NIPT, such as its accuracy in identifying genetic disorders and non-invasive nature, which ultimately restricts its population acceptance. High Cost and Limited Insurance Coverage One of the biggest problems in Saudi Arabia is the high expense of non-invasive prenatal testing (NIPT). Although NIPT has advantages over conventional invasive testing, many pregnant women cannot afford it since it is frequently not covered by insurance. According to research, just 30% of participants were prepared to spend 1,500 SAR (about $400 USD), whereas 74.1% of participants would be willing to undergo NIPT if it were free. Access to NIPT is restricted by this cost burden, especially for those with lower incomes. Because of this, a lot of women could choose more risky or less accurate screening techniques, which would further exacerbate the disparity in access to high-quality prenatal care. Key Attributes Report Attribute Details No. of Pages 200 Forecast Period 2024-2033 Estimated Market Value (USD) in 2024 $46.3 Million Forecasted Market Value (USD) by 2033 $143.1 Million Compound Annual Growth Rate 13.3% Regions Covered Saudi Arabia Key Topics Covered1. Introduction2. Research Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Saudi Arabia Non-Invasive Prenatal Testing Market6. Market Share Analysis6.1 Component6.2 Application6.3 End User7. Component7.1 Instruments7.2 Kits and Reagents7.3 Services8. Application8.1 Down Syndrome (Trisomy 21)8.2 Edwards Syndrome (Trisomy 18)8.3 Patau Syndrome (Trisomy 13)8.4 Turner Syndrome8.5 Other Applications9. End User9.1 Hospitals9.2 Diagnostic Labs10. Porter's Five Analysis10.1 Bargaining Power of Buyers10.2 Bargaining Power of Suppliers10.3 Degree of Rivalry10.4 Threat of New Entrants10.5 Threat of Substitutes11. SWOT Analysis11.1 Strength11.2 Weakness11.3 Opportunity11.4 Threat12. Key Players Analysis12.1 Eurofins Scientific12.2 F. Hoffmann-La Roche Ltd.12.3 Invitae Corporation12.4 Illumina Inc.12.5 Natera Inc.12.6 Centogene N.V.12.7 QiagenFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Non-Invasive Prenatal Testing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
3 days ago
- Business
- Yahoo
Asia-Pacific NIPT Market to Hit USD 4.57 Billion by 2033: Growth Driven by Technological Advancements and Healthcare Reforms
Developed countries like Japan and South Korea have integrated NIPT into healthcare systems, while emerging markets like China and India are witnessing rapid adoption due to improved healthcare access and insurance reforms Asia-Pacific Non-Invasive Prenatal Testing Market Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Non-Invasive Prenatal Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to offering. The Asia-Pacific Non-Invasive Prenatal Testing Market is expected to reach US$ 4.57 billion by 2033 from US$ 1.33 billion in 2024, with a CAGR of 14.64% from 2025 to 2033. The market is expanding due to factors such the demand for precise and prompt prenatal diagnoses, the usage of advanced genetic technology, and the aging of mothers. The introduction of healthcare reforms in several Asia-Pacific countries and the extension of insurance coverage for prenatal care are further encouraging the usage of NIPT. The non-invasive prenatal testing (NIPT) market in Asia-Pacific is expanding quickly due to factors including growing mother age, improved genetic testing technology, and growing awareness of prenatal care. Asia-Pacific, one of the most populated and varied regions, is home to nations with a range of socioeconomic backgrounds and healthcare infrastructure levels. This discrepancy has made NIPT adoption both difficult and possible. NIPT is becoming a common component of prenatal treatment in nations with highly developed healthcare systems, such as South Korea, Singapore, and Japan, especially for high-risk pregnancies. Meanwhile, as healthcare access improves and more women look for safer, more accurate screening alternatives, the demand for NIPT is rising quickly in emerging areas like China, India, and Southeast Asia. The Asia-Pacific region's more developed nations have robust healthcare systems, supportive governments, and high public awareness, all of which contribute to the NIPT industry. Due to its integration into national screening programs for high-risk pregnancies, NIPT is widely available and reasonably priced. Effective use of NIPT to identify chromosomal abnormalities and guide pregnancy treatment is ensured by the availability of qualified genetic counselors and established medical procedures. Technological advancements and the accessibility of sophisticated screening techniques in these areas further propel market growth. Less developed regions of the Asia-Pacific still face difficulties, nevertheless. NIPT is still a luxury service that is expensive and scarce in nations with inadequate healthcare resources or where healthcare systems are still developing. Barriers to broader acceptability also include ethical issues about genetic screening and cultural views on prenatal testing. Therefore, it is necessary to overcome both cultural opposition and infrastructure constraints in order to expand the NIPT market in these nations. For NIPT to become more widely available and reasonably priced throughout the Asia-Pacific region, it will be essential to maintain investments in healthcare infrastructure, public awareness initiatives, and legislative backing. The high cost of these tests, leading to relatively low affordability in many developing countries, will limit their adoption. According to an article published by Future Medicine, the average cost of non-invasive prenatal testing in India is around USD 350 to USD 400. According to an article published by the Australian Broadcasting Corporation in May 2022, an NIPT costs around USD 500 and is a high out-of-pocket cost during pregnancy, pressuring families to terminate their pregnancies after the first positive test for Down's syndrome. This has limited their uptake in emerging countries. Growth Drivers for the Asia-Pacific Non-Invasive Prenatal Testing Market Advancements in Genetic Testing Technology Non-invasive prenatal testing (NIPT) is now much more accurate, quick, and affordable because to developments in genetic testing technology, especially next-generation sequencing (NGS) and bioinformatics. Rapid fetal DNA analysis from maternal blood samples is made possible by NGS, which improves the test's sensitivity and specificity, particularly for identifying chromosomal disorders like Down syndrome. Advances in bioinformatics enable the rapid processing of enormous volumes of genetic data, cutting down on testing expenses and time. Because of these technical developments, NIPT is now more widely available to pregnant mothers in both developed and growing Asia-Pacific economies. As a result, NIPT is becoming more widely used worldwide, providing safer and more precise prenatal screening alternatives. Government Support and National Screening Programs The expansion of non-invasive prenatal testing (NIPT) throughout Asia is mostly due to government assistance and national screening initiatives. Because NIPT has been included into national healthcare systems in nations like Singapore and Japan, expecting moms may easily obtain and use it. These countries lower the dangers associated with intrusive testing techniques while also improving early diagnosis of chromosomal abnormalities by providing NIPT as part of standard prenatal care. Furthermore, NIPT's wider acceptability is facilitated by public health campaigns that inform patients of its advantages. Government support makes NIPT a dependable and crucial instrument in prenatal care throughout the area by helping to standardize its usage. Expansion of Private Healthcare A wider population now has far better access to non-invasive prenatal testing (NIPT) because to the growth of private healthcare providers in nations like Thailand and India. Private healthcare institutions provide advanced testing alternatives, such as NIPT, that might not be available in public systems because to the growing need for quicker and more thorough care. This expansion is especially helpful for pregnant moms who want more individualized care or faster outcomes. A greater variety of patients may now get sophisticated prenatal screening as private healthcare providers increase NIPT's accessibility and price, therefore closing the wealth gap between high- and middle-income groups. Additionally, this growth promotes healthy competition, which raises the standard and effectiveness of prenatal care. Challenges in the Asia-Pacific Non-Invasive Prenatal Testing Market Inconsistent Regulation and Standardization The Asia-Pacific non-invasive prenatal testing (NIPT) industry has major obstacles due to inconsistent legislation and standards. Different nations have different NIPT regulatory frameworks, which causes variations in certification, quality assurance, and testing procedures. The accuracy and dependability of results may be impacted in some areas by inadequate laboratory oversight or unclear test process recommendations. The safety and efficacy of the tests may be questioned as different nations may provide NIPT services of varying quality in the absence of uniform rules. This discrepancy can erode patient faith in NIPT, particularly in nations with laxer regulations, which would prevent the technique from being widely adopted and trusted. Infrastructure Challenges in Emerging Markets Non-invasive prenatal testing (NIPT) may not be widely available in developing nations with underdeveloped healthcare systems, especially in rural or isolated places. Modern medical facilities and specialist labs, which are usually concentrated in metropolitan areas, are frequently necessary for the availability of NIPT. Therefore, access to this advanced prenatal screening may be severely hampered for pregnant moms in impoverished or rural areas. Due to limited availability to NIPT, a sizable portion of the population is unable to take advantage of early genetic abnormality diagnosis. Investment in medical facilities, better diagnostic service distribution, and efforts to increase access to NIPT in less accessible areas are all necessary to address these infrastructural issues and guarantee more equal access to healthcare. Key Attributes Report Attribute Details No. of Pages 200 Forecast Period 2024-2033 Estimated Market Value (USD) in 2024 $1.4 Billion Forecasted Market Value (USD) by 2033 $4.58 Billion Compound Annual Growth Rate 14% Regions Covered Asia-Pacific Key Topics Covered1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Asia-Pacific Non-Invasive Prenatal Testing Market6. Market Share Analysis6.1 Component6.2 Application6.3 End User7. Asia-Pacific - Countries Non-Invasive Prenatal Testing Market7.1 China7.2 Japan7.3 India7.4 Australia7.5 South Korea7.6 Thailand7.7 Malaysia7.8 Indonesia7.9 New Zealand8. Component8.1 Instruments8.2 Kits and Reagents8.3 Services9. Application9.1 Down Syndrome (trisomy 21)9.2 Edwards Syndrome (trisomy 18)9.3 Patau Syndrome (trisomy 13)9.4 Turner Syndrome9.5 Other Applications10. End User10.1 Hospitals10.2 Diagnostic Labs11. Porter's Five Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis13.1 Eurofins Scientific13.1.1 Overview13.1.2 Key Persons13.1.3 Recent Development & Strategies13.1.4 Financial Insight13.2 F. Hoffmann-La Roche Ltd.13.3 Invitae Corporation13.4 Illumina Inc.13.5 Natera Inc.13.6 Centogene N.V.13.7 Qiagen For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Non-Invasive Prenatal Testing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Korea Herald
16-05-2025
- Business
- Korea Herald
Gene Solutions and NEWCL Forge Strategic Partnership to Advance Genetic Testing in Taiwan
NEW TAIPEI CITY, May 16, 2025 /PRNewswire/ -- In a groundbreaking move, Gene Solutions, a leader in prenatal and oncology genetic testing, and NEWCL Biomedical Laboratory, Taiwan's pioneering clinical laboratory with LDTs certification, have joined forces to establish an advanced Next-Generation Sequencing (NGS) laboratory in Taiwan. This collaboration was sealed with the signing of a Memorandum of Understanding (MoU) at NEWCL's state-of-the-art facility in New Taipei City. Gene Solutions is set to bring its cutting-edge NIPT tests (trademarked as triSure™) and oncology tests (SPOT-MAS early cancer detection, K-TRACK, K-4CARE comprehensive genomic profiling, ctDNA-MRD monitoring) to Taiwan, expanding its footprint in the APAC region. These innovative tests, trusted by millions across Asia, will soon be available to Taiwanese patients, offering unparalleled accuracy and reliability. NEWCL, established in 2012 and part of DITECH Enterprise, is a premier biomedical laboratory located in New Taipei City. It serves major hospitals and medical service units across Taiwan, providing a wide range of bio testing services including HBV, HCV, Genotype, and Allergen Chip testing. Combining Gene Solutions' expertise in NGS test development with NEWCL's robust laboratory capabilities, this partnership aims to create one of Taiwan's most advanced NGS laboratories. This facility will cater to the growing demand for sophisticated DNA testing in prenatal care and precision oncology, ensuring Taiwanese patients have access to the latest advancements in genetic testing. With the anticipated launch of the partnered NGS lab and tech-transfer in 2025, both companies will explore the commercialization of NGS testing in Taiwan through NEWCL's established commercial network, including TUNG-BO Medical Ltd. Gene Solutions, with its strong foundation in Molecular Biology Research and Genetic Counseling, will drive scientific conferences, medical training, and research collaborations with hospitals and medical service units across Taiwan. In prenatal care, Gene Solutions plans to integrate its unique carrier screening (mother recessive genes) and single-gene screening (de-novo mutations of the fetus) into renowned Non-invasive Prenatal Testing (NIPT). This innovative approach has already proven successful in Southeast Asia, where over one million pregnant women have benefited from triSure tests. In oncology, the collaboration aims to bring Gene Solutions' latest Comprehensive Genomic, Transcriptomic Profiling and ctDNA Molecular Residual Disease tests K-TRACK, K-4CARE to Taiwanese medical oncologists. Currently, samples for such advanced tests must be sent overseas, which is costly and time-consuming. This partnership will eliminate these barriers, providing faster and more cost-effective solutions for cancer patients in Taiwan. Furthermore, with the commitment from NEWCL and Gene Solutions to the scientific community, oncology researchers in Taiwan will have enhanced opportunities to explore novel therapeutic biomarkers for precision oncology. Dr. Nguyen Hoai Nghia, Co-founder and CEO of Gene Solutions, expressed his enthusiasm: "We are excited to collaborate with leading partners in Asia to accelerate the adoption of cutting-edge precision healthcare technology. NEWCL's expertise in laboratory operations and DITECH's market experience will be invaluable in making these advancements accessible in Taiwan." Ms. Ku, Chi-Ming, Director of NEWCL Biomedical Laboratory, also shared: "NEWCL is thrilled to partner with Gene Solutions to bring the most advanced NGS applications to Taiwan. This collaboration marks a significant milestone in our mission to provide cutting-edge genetic testing services. By combining our laboratory excellence with Gene Solutions' innovation in prenatal and oncology diagnostics, we are poised to transform the landscape of precision medicine for patients across Taiwan." This strategic partnership is poised to transform precision healthcare in Taiwan, bringing hope and advanced solutions to patients and healthcare providers alike. About Gene Solutions Gene Solutions, a multinational biotech company, offers a comprehensive genetic testing portfolio utilizing Next-Generation Sequencing (NGS) and Artificial Intelligence algorithms. The testing services include cell-free DNA non-invasive prenatal testing (NIPT), circulating tumor DNA (ctDNA) cancer screening, genomic profiling, and treatment monitoring. Established in 2017, Gene Solutions operates a network of seven NGS laboratories, including two central CAP-accredited laboratories in Singapore and Vietnam. With over two million tests provided to patients, we remain committed to delivering accessible genetic testing services to more than 4,500 hospitals and clinics across Asia. To learn more about Gene Solutions, please visit
Yahoo
16-05-2025
- Business
- Yahoo
Gene Solutions and NEWCL Forge Strategic Partnership to Advance Genetic Testing in Taiwan
NEW TAIPEI CITY, May 16, 2025 /PRNewswire/ -- In a groundbreaking move, Gene Solutions, a leader in prenatal and oncology genetic testing, and NEWCL Biomedical Laboratory, Taiwan's pioneering clinical laboratory with LDTs certification, have joined forces to establish an advanced Next-Generation Sequencing (NGS) laboratory in Taiwan. This collaboration was sealed with the signing of a Memorandum of Understanding (MoU) at NEWCL's state-of-the-art facility in New Taipei City. Gene Solutions is set to bring its cutting-edge NIPT tests (trademarked as triSure™) and oncology tests (SPOT-MAS early cancer detection, K-TRACK, K-4CARE comprehensive genomic profiling, ctDNA-MRD monitoring) to Taiwan, expanding its footprint in the APAC region. These innovative tests, trusted by millions across Asia, will soon be available to Taiwanese patients, offering unparalleled accuracy and reliability. NEWCL, established in 2012 and part of DITECH Enterprise, is a premier biomedical laboratory located in New Taipei City. It serves major hospitals and medical service units across Taiwan, providing a wide range of bio testing services including HBV, HCV, Genotype, and Allergen Chip testing. Combining Gene Solutions' expertise in NGS test development with NEWCL's robust laboratory capabilities, this partnership aims to create one of Taiwan's most advanced NGS laboratories. This facility will cater to the growing demand for sophisticated DNA testing in prenatal care and precision oncology, ensuring Taiwanese patients have access to the latest advancements in genetic testing. With the anticipated launch of the partnered NGS lab and tech-transfer in 2025, both companies will explore the commercialization of NGS testing in Taiwan through NEWCL's established commercial network, including TUNG-BO Medical Ltd. Gene Solutions, with its strong foundation in Molecular Biology Research and Genetic Counseling, will drive scientific conferences, medical training, and research collaborations with hospitals and medical service units across Taiwan. In prenatal care, Gene Solutions plans to integrate its unique carrier screening (mother recessive genes) and single-gene screening (de-novo mutations of the fetus) into renowned Non-invasive Prenatal Testing (NIPT). This innovative approach has already proven successful in Southeast Asia, where over one million pregnant women have benefited from triSure tests. In oncology, the collaboration aims to bring Gene Solutions' latest Comprehensive Genomic, Transcriptomic Profiling and ctDNA Molecular Residual Disease tests K-TRACK, K-4CARE to Taiwanese medical oncologists. Currently, samples for such advanced tests must be sent overseas, which is costly and time-consuming. This partnership will eliminate these barriers, providing faster and more cost-effective solutions for cancer patients in Taiwan. Furthermore, with the commitment from NEWCL and Gene Solutions to the scientific community, oncology researchers in Taiwan will have enhanced opportunities to explore novel therapeutic biomarkers for precision oncology. Dr. Nguyen Hoai Nghia, Co-founder and CEO of Gene Solutions, expressed his enthusiasm: "We are excited to collaborate with leading partners in Asia to accelerate the adoption of cutting-edge precision healthcare technology. NEWCL's expertise in laboratory operations and DITECH's market experience will be invaluable in making these advancements accessible in Taiwan." Ms. Ku, Chi-Ming, Director of NEWCL Biomedical Laboratory, also shared: "NEWCL is thrilled to partner with Gene Solutions to bring the most advanced NGS applications to Taiwan. This collaboration marks a significant milestone in our mission to provide cutting-edge genetic testing services. By combining our laboratory excellence with Gene Solutions' innovation in prenatal and oncology diagnostics, we are poised to transform the landscape of precision medicine for patients across Taiwan." This strategic partnership is poised to transform precision healthcare in Taiwan, bringing hope and advanced solutions to patients and healthcare providers alike. About Gene Solutions Gene Solutions, a multinational biotech company, offers a comprehensive genetic testing portfolio utilizing Next-Generation Sequencing (NGS) and Artificial Intelligence algorithms. The testing services include cell-free DNA non-invasive prenatal testing (NIPT), circulating tumor DNA (ctDNA) cancer screening, genomic profiling, and treatment monitoring. Established in 2017, Gene Solutions operates a network of seven NGS laboratories, including two central CAP-accredited laboratories in Singapore and Vietnam. With over two million tests provided to patients, we remain committed to delivering accessible genetic testing services to more than 4,500 hospitals and clinics across Asia. To learn more about Gene Solutions, please visit Media Contact: pr@ View original content to download multimedia: SOURCE Gene Solutions Genomics Pte Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
News18
11-05-2025
- Health
- News18
Your Genes, Your Health: Why Genetic Testing Is the Smartest Wellness Move You Can Make
Last Updated: Genetic testing is transforming preventive healthcare by revealing hidden disease risks and empowering individuals—especially women—to make informed choices By now, we're used to thinking of our genes as the blueprint of who we are. But what if they could also serve as a map—guiding us through critical decisions about our health, long before any symptoms show up? With the rise of affordable, accessible genetic testing, that future is already here. Take the chilling cases of sudden cardiac deaths among elite athletes or seemingly healthy young adults diagnosed with advanced cancers—often without warning or obvious risk factors. According to Dr. Ashok Gopinath, Head – Partner Development, Strand Life Sciences, such scenarios, though rare, highlight a crucial truth: 'It is quite well established that beyond advanced age and lifestyle, genes play a significant role in the onset of diseases like cancer and cardiovascular conditions." In fact, about 10% of all cancers have a hereditary basis. 'Inherited BRCA mutations, for instance, confer a 69–72% lifetime risk for breast cancer and a 17–44% risk for ovarian cancer," adds Dr. Gopinath. That's compared to baseline population risks of just 5–12% and less than 1%, respectively. Despite this, genetic testing has traditionally been recommended reactively—after symptoms, or a strong family history, surface. But times are changing. Thanks to newer, non-invasive screening tools and plummeting costs, genetic testing is no longer a diagnostic tool of last resort—it's emerging as a proactive strategy. Tests like Genomic Health Insights (GHI) by Strand Life Sciences now allow individuals to screen for over 280 adult-onset genetic disorders, including various cancers and heart diseases, even in the absence of symptoms. 'We truly are fortunate to live in a time where every individual is empowered to take predictive tests and proactively understand their risk," says Dr. Gopinath. As someone who treats hundreds of women facing fertility struggles, Dr. Lekhi sees genetic testing as a revolution. 'From uncovering hidden causes of infertility and miscarriage to detecting risks for PCOS, endometriosis, or premature ovarian failure, your DNA contains vital clues," she explains. And it doesn't stop there. For patients undergoing IVF, preimplantation genetic testing (PGT) helps select the healthiest embryos, thereby increasing the chances of a successful pregnancy. Non-invasive prenatal testing (NIPT), on the other hand, offers peace of mind by detecting chromosomal abnormalities early in pregnancy. Most importantly, genetic insights can help women take control of their reproductive futures. 'Whether it's freezing eggs at 20 or addressing inherited conditions before they compromise fertility, the possibilities are staggering," says Dr. Lekhi. 'Your genes aren't your fate—they're your map. And genetic screening? That's the compass guiding you intelligently." As science gives us more tools to understand our biology, the message is clear: we no longer have to wait for a diagnosis to act. In the evolving landscape of personalised healthcare, knowing your genetic risk may be the most empowering move you can make—for today and for the years to come. First Published: May 11, 2025, 17:50 IST
